caa a22 4500 605520836 CHVBK 20210128100737.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s00223-015-0037-y doi (NATIONALLICENCE)springer-10.1007/s00223-015-0037-y Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs [Elektronische Daten] [Johanna Driessen, Hein van Onzenoort, Jakob Starup-Linde, Ronald Henry, Andrea Burden, Cees Neef, Joop van den Bergh, Peter Vestergaard, Frank de Vries] Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs that might have a potential beneficial effect on bone metabolism. Data on the effect of GLP-1 RAs and fracture risk are lacking. The aim of the present study was to investigate the association between the use of GLP-1 and the risk of fracture. A case-control study was performed using Danish National Health Service data. Cases were those who sustained a fracture and controls were those without a fracture during the study period (2007-2011), all aged 18years and above. Conditional logistic regression estimated the odds ratios (OR) of fracture with current use of DPP4-I use. Analyses were adjusted for comorbidities and recent drug use. Among cases (n=229,114), there were 6993 current non-insulin anti-diabetic drug (NIAD) users (excluding incretin users) and 255 GLP-1 RA users. Similarly, among controls (n=229,114), 7209 were NIAD users (excluding incretin users) and 220 were GLP-1 RA users. Current GLP-1 RA use was not associated with a decreased risk of fracture [adjusted (adj.) OR 1.16; 95% CI 0.83-1.63]. Osteoporotic fracture risk was also not associated with current GLP-1 RA use (adj. OR 0.78; 95% CI 0.44-1.39). In our nation-wide case-control study, we identified that the use of GLP-1 RA was not associated with fracture risk as compared to the use of other anti-hyperglycemic drugs. Additionally, current GLP-1 RA use, stratified by cumulative or average daily dose, is not associated with fracture risk. Further research should focus on long-term use of GLP-1 RA and fracture risk. The Author(s), 2015 GLP-1 RA nationallicence Fracture nationallicence Type 2 diabetes mellitus nationallicence Case-control nationallicence Driessen Johanna Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut van Onzenoort Hein Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands aut Starup-Linde Jakob Department of Clinical Medicine, Aalborg University, Aalborg, Denmark aut Henry Ronald Department of Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands aut Burden Andrea Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut Neef Cees Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut van den Bergh Joop Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands aut Vestergaard Peter Department of Clinical Medicine, Aalborg University, Aalborg, Denmark aut de Vries Frank Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut Calcified Tissue International Springer US; http://www.springer-ny.com 97/5(2015-11-01), 506-515 0171-967X 97:5<506 2015 97 223 https://doi.org/10.1007/s00223-015-0037-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00223-015-0037-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Driessen Johanna Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- van Onzenoort Hein Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands aut NATIONALLICENCE 700 1- Starup-Linde Jakob Department of Clinical Medicine, Aalborg University, Aalborg, Denmark aut NATIONALLICENCE 700 1- Henry Ronald Department of Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands aut NATIONALLICENCE 700 1- Burden Andrea Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- Neef Cees Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- van den Bergh Joop Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands aut NATIONALLICENCE 700 1- Vestergaard Peter Department of Clinical Medicine, Aalborg University, Aalborg, Denmark aut NATIONALLICENCE 700 1- de Vries Frank Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands aut NATIONALLICENCE 773 0- Calcified Tissue International Springer US; http://www.springer-ny.com 97/5(2015-11-01), 506-515 0171-967X 97:5<506 2015 97 223